A 15-year clinical example in conservative long-term aesthetic planning, what authenticity looks like across a decade
Introduction: The Long View
Most aesthetic treatment plans span 12 to 18 months. Core Aesthetics plans in years.
This page follows a fictional but realistic 15-year patient journey (age 38 to 53) through the Core Longevity Plan framework. It shows how conservative, documented planning maintains facial authenticity while preventing cumulative over-treatment.
The 15-Year Clinical example: Sarah, Age 38 to 53
Year 0 (Age 38): Initial Consultation and Core Method Planning
Presentation: Sarah is 38, professionally active, notice subtle softening of cheek definition and mild under-eye hollowing, especially when tired. Not concerned about movement lines. Goals: ‘Look refreshed, not different. Not overdone.’
Assessment: Stage 2/Early Stage 3 ageing. Malar fat beginning superior-medial migration. Good skin quality. Stable, conservative candidate.
Plan: Baseline HA protocol = 0.5mL malar + 0.2mL periorbital, no botulinum. Document photos, measurements, rationale.
Delivery (Month 0): 0.5mL malar (single injection, zygomatic region), 0.2mL periorbital. Total: 0.7mL HA.
Review (Week 8): Result is subtle, balanced, refreshed. Sarah is pleased. Baseline photos documented. Projected maintenance timeline: Year 1 re-treatment at 0.7mL total; Year 2 similar; assess for expansion at Year 3.
Year 1 (Age 39): First Maintenance Cycle
Presentation: Sarah returns happy with result. Cheeks remain defined. Under-eye remains improved but slightly less ‘fresh’ than at 8-week peak (expected absorption ~40%). Requests maintenance.
Assessment: Cumulative HA estimate: ~0.4 to 0.5mL remaining from Year 0 + new injection = ~0.9 to 1.0mL total HA + fibroblast-produced HA.
Plan: Repeat baseline protocol (0.5mL malar + 0.2mL periorbital).
Delivery (Month 12): 0.5mL malar, 0.2mL periorbital. Total: 0.7mL new HA.
Review (Week 8): Cumulative effect is now visible, Sarah’s cheeks are noticeably fuller than original baseline, but she perceives this as ‘maintenance.’ Clinician documents: ‘Appearance is slightly fuller than Year 0 baseline, but patient is satisfied. Cumulative volume estimate: ~0.9mL HA. Continue monitoring.’
Year 2 to 3 (Age 40 to 41): Expanding the Plan
Presentation: By Year 2, Sarah’s cheeks are visibly fuller. She’s experiencing natural ageing progression (early nasolabial folds deepening, fine lines around eyes becoming more apparent). She’s considering whether to expand treatment.
Assessment: Stage 3 ageing now clearly present. Cumulative HA in malar region is ~1.1 to 1.2mL (at upper end of appropriate range for her anatomy). Nasolabial folds are medically treatable concern, not preventative.
Year 2 Plan: Repeat malar/periorbital at baseline (0.7mL). Do not expand.
Year 3 Plan: If nasolabial improvement desired, consider adding 0.2mL nasolabial filler (different region; malar treatment remains consistent at 0.7mL). Introduce subtle glabella botulinum (8 units) for fine line softening.
Rationale: Wait until cumulative malar HA has stabilized and been documented over two cycles before expanding to new regions. Prevents simultaneous escalation across multiple areas.
Year 4 to 5 (Age 42 to 43): Transition and Adaptation
Presentation: Sarah is experiencing perimenopause. Hormone shifts affecting skin quality and hydration. Crow’s feet becoming more apparent. She’s considering whether botulinum would help expression.
Assessment: Stage 3 ageing with early Stage 4 characteristics. Cumulative HA is now ~1.3 to 1.4mL across three regions (malar, periorbital, nasolabial). Suitable for modest botulinum addition.
Plan: Year 4: Maintain existing HA protocol (0.5mL malar, 0.2mL periorbital, 0.2mL nasolabial = 0.9mL total). Add modest botulinum (12 units crow’s feet + 6 units glabella = 18 units total).
Year 5: Repeat above if Sarah is satisfied. If perimenopause-driven hydration loss becomes significant concern, consider deferring one HA cycle to assess baseline (often hydration improves post-menopause).
Year 6 to 10 (Age 44 to 48): Stable Maintenance
Presentation: Perimenopause resolves. Sarah’s treatment has become established routine. She’s maintained across regions: malar, periorbital, nasolabial, and consistent botulinum (crow’s feet + glabella).
Assessment: Stage 3/4 ageing. Cumulative HA is stable at ~1.2 to 1.4mL across regions. Muscle tone maintained by regular botulinum.
Plan: Annual maintenance cycle: 0.9mL HA (malar 0.5, periorbital 0.2, nasolabial 0.2) + 18 units botulinum (glabella 6, crow’s feet 12). Document every cycle. Re-assess cumulative adequacy annually.
Years 6 to 10 variation: At Year 8, Sarah mentions family stress and skin quality decline. Clinician suggests deferring one HA cycle to assess whether stress-driven hydration loss is primary driver (often it is). Year 8 cycle: botulinum only. Year 9: resume full HA protocol.
Key: Treatment is responsive to life circumstances. Not rigid protocol, but documented flexibility.
Year 11 to 15 (Age 49 to 53): Long-Term Sustainability and Reassessment
Presentation: Sarah is now 53, post-menopausal, entering late Stage 3/early Stage 4 ageing structurally. She’s remained on consistent treatment protocol for 13 years. She’s noticing deeper nasolabial folds and considering whether she needs ‘more’ treatment.
Assessment: Cumulative HA is ~1.3mL across regions (well within sustainable range for her anatomy over 15 years). Botulinum response remains good. Nasolabial deepening is stage-appropriate ageing, not failure of treatment.
Plan: Year 15 assessment is comprehensive reassessment: Baseline photos from Year 0 vs. Year 15. Discuss: Your cheeks remain defined. Your expression remains natural. Your under-eyes look refreshed. The nasolabial lines are deepening, that is stage-appropriate ageing. We can manage this by adding very minimal nasolabial filler, but we should discuss whether this is important to you or whether you are comfortable with some ageing being visible.
Dosing Philosophy: Conservative-by-Design Math
Year 0: 0.7mL total HA (0.5 malar + 0.2 periorbital)
Year 1: +0.7mL new = ~0.4mL remaining + 0.7mL new = 1.1mL total cumulative
Year 2: +0.7mL new = ~0.6 to 0.7mL remaining + 0.7mL new = 1.3 to 1.4mL cumulative
Year 3: +0.9mL new (added nasolabial) = ~0.8mL remaining + 0.9mL new = 1.7mL cumulative (upper range for this anatomy)
Average annual increase: (1.7mL Year 3 – 0.7mL Year 0) / 3 years = 0.33mL increase per year = appropriate.
Contrast this with typical escalation: Year 0: 0.7mL → Year 1: 0.8mL → Year 2: 0.9mL → Year 3: 1.0mL + 0.3mL nasolabial = 1.3mL new per cycle. By Year 5: ~2.5 to 3.0mL cumulative. This is unsustainable.
Frequently asked questions
How do I know if my treatment timeline is realistic?
A realistic timeline shows gradual incremental changes, not dramatic transformations. Your practitioner should document baseline photos and discuss what is reasonably achievable given your starting anatomy and age. If claims of ‘looking 10 years younger’ appear early, that is a red flag, sustainable improvement occurs over years, not weeks.
Can I stop treatment and go back to baseline?
Yes. Unlike some surgical procedures, injectables are reversible. HA is metabolised over months; stopping means gradually returning to baseline over 6 to 12 months. Botulinum effect also reverses. Some patients find that after years of treatment, they prefer subtle lines to the effort of ongoing maintenance, that is a valid choice.
What if I want to ‘reset’ and start fresh with a new practitioner?
Bring your documentation: photos, treatment dates, product types (though brand names are not essential), volumes, and areas treated. A competent new practitioner can assess cumulative effects and plan accordingly. If documentation is poor or absent, request a 3 to 6 month pause to allow metabolisation before restarting, this gives you a clearer baseline.